BIT:1BIIB - Euronext Milan - US09062X1037 - Common Stock - Currency: EUR
BIT:1BIIB (3/5/2025, 7:00:00 PM)
131.8
-15.4 (-10.46%)
The current stock price of 1BIIB.MI is 131.8 EUR.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
0QF.DE | MODERNA INC | N/A | 13.19B | ||
1MRNA.MI | MODERNA INC | N/A | 12.34B |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7570
Company Website: https://www.biogen.com/
Investor Relations: https://investors.biogen.com
Phone: 17814642000
The current stock price of 1BIIB.MI is 131.8 EUR. The price decreased by -10.46% in the last trading session.
The exchange symbol of BIOGEN INC is 1BIIB and it is listed on the Euronext Milan exchange.
1BIIB.MI stock is listed on the Euronext Milan exchange.
42 analysts have analysed 1BIIB.MI and the average price target is 219.33 EUR. This implies a price increase of 66.41% is expected in the next year compared to the current price of 131.8. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOGEN INC (1BIIB.MI) has a market capitalization of 19.21B EUR. This makes 1BIIB.MI a Large Cap stock.
BIOGEN INC (1BIIB.MI) currently has 7570 employees.
The Revenue of BIOGEN INC (1BIIB.MI) is expected to decline by -2.86% in the next year. Check the estimates tab for more information on the 1BIIB.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
1BIIB.MI does not pay a dividend.
BIOGEN INC (1BIIB.MI) will report earnings on 2025-02-12, after the market close.
The PE ratio for BIOGEN INC (1BIIB.MI) is 8.39. This is based on the reported non-GAAP earnings per share of 15.71 and the current share price of 131.8 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1BIIB.MI.
ChartMill assigns a technical rating of 3 / 10 to 1BIIB.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1BIIB.MI. While 1BIIB.MI has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months 1BIIB.MI reported a non-GAAP Earnings per Share(EPS) of 15.71. The EPS increased by 3.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.81% | ||
ROA | 5.7% | ||
ROE | 9.87% | ||
Debt/Equity | 0.28 |
ChartMill assigns a Buy % Consensus number of 75% to 1BIIB.MI. The Buy consensus is the average rating of analysts ratings from 42 analysts.
For the next year, analysts expect an EPS growth of 10.8% and a revenue growth -2.86% for 1BIIB.MI